Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck, Upsher-Smith pharmaceuticals, generics news

The U.S. Supreme Court remanded two cases involving pay-for-delay deals between branded and generic drug manufacturers back to the U.S. Court of Appeals for the Third Circuit. SCOTUS

Read the full 286 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE